Background:In vivo pharmacodynamic evaluation plays a vital role in basic research and therapeutic drug development. Pharmacodynamic research can help define the clinical potential of a new drug and identify the strengths and weaknesses in comparison to other drugs already on the market. Animal tumor models focus on spontaneous tumors transplanted models. Transplanted tumors have the advantages of definite characteristics: rapid and reliable tumor growth short experimental period, models for various types.
Methods:Alternative animal models can be applied as cost-effective research tools to conduct intensive and reliable experiments for personalized research purposes.
Advantages:Prefabricated models can be completed in 4 weeks from the bearing of tumor to the end of administration, and we have abundant antibodies and cell lines. We are committed to offer batch-to batch consistency in cell resources with high stability and low within-group variation.
Cases: Since the establishment of Sanyou Bio in vivo platform in 2018, we have been committed to provide you with 150+ small animal models and 56 days of in vivo efficacy rapid efficiency evaluation services. By April 2022, we have successfully developed 60+ tumor models, covering major tumors, and we have successfully completed efficacy evaluation of a series of targets such as TNFR2 and CD39, and accumulated extensive project experience for different molecular types.
Service Overviews
Background:In vivo pharmacodynamic evaluation plays a vital role in basic research and therapeutic drug development. Pharmacodynamic research can help define the clinical potential of a new drug and identify the strengths and weaknesses in comparison to other drugs already on the market. Animal tumor models focus on spontaneous tumors transplanted models. Transplanted tumors have the advantages of definite characteristics: rapid and reliable tumor growth short experimental period, models for various types.
Methods:Alternative animal models can be applied as cost-effective research tools to conduct intensive and reliable experiments for personalized research purposes.
Advantages:Prefabricated models can be completed in 4 weeks from the bearing of tumor to the end of administration, and we have abundant antibodies and cell lines. We are committed to offer batch-to batch consistency in cell resources with high stability and low within-group variation.
Cases: Since the establishment of Sanyou Bio in vivo platform in 2018, we have been committed to provide you with 150+ small animal models and 56 days of in vivo efficacy rapid efficiency evaluation services. By April 2022, we have successfully developed 60+ tumor models, covering major tumors, and we have successfully completed efficacy evaluation of a series of targets such as TNFR2 and CD39, and accumulated extensive project experience for different molecular types.
Service Contents
Services
Service Details
Client Provides
Deliverables and Standards
Time
Efficacy evaluation (not prefabricated)
1. Cell line construction
2. Cell line validation
3. STR analysis (Optional)
4. Tumor growth curve
5. Model development
6. Efficiency evaluation
1. Target MOA
2. Antibody
3. Experimental scheme
1. Quality report
2. Tumor growth curve
3. Report
6-8 weeks
Efficacy evaluation (prefabricated)
Efficacy evaluation
1. Target MOA
2. Antibody
Report
~4 weeks
Multicolor flow Cytometry
Tissue/blood cell subtype flow cytometry
Biomarker
Report
1~3 days
Cytokine/enzyme detection
1. Multi/single cytokines
2.Enzymes, etc
Biomarker
Report
1~3 days
Pharmacokinetic analysis
1.PK experiment
2.PK analysis
1. Target MOA
2. Antibody
Report
45 days
Service Highlights
1. A Wide Array of Mouse Strains and Disease Models
Sanyou Bio has a wide array of transgenic mice and different immunodeficient mice to meet your demands, and 60+ tumor models have been successfully established, covering major clinical tumor species.
2. Standardized Laboratory Animal Facility
Sanyou Bio has rented SPF /Elite animal facility, high-quality laboratory mice and meet animal ethics requirements.
3. High Quality One-stop Service
Sanyou Bio is committed to provide you with one-stop high-quality services, from antibody production and purification, tumor cell line construction and customized in vivo efficacy models.
4. Excellent Experience in Project
Sanyou Bio is highly experienced and focused on xenograft tumor models for the discovery novel anti-tumor agents (covering Antibodies, Bi/Tri-specific Antibody and Antibody–drug conjugates) with professional knowledge and comprehensive capability.
5. Fast and High-quality Delivery in 56 days
Sanyou Bio has a broad range of human xenograft tumor cell lines that are commonly used and provide with customized service to evaluate novel anti-tumor agents in a timely and cost-effective method.
Service Features
1. Abundant mouse strains and tumor models
1.1. Abundant mouse strains
Sanyou Bio is committed to provide you with alternative strains for in vivo efficiency evaluation, corresponding to mechanisms of action, molecular types, mouse strains.
Animal Strain
Target Mechanism
Molecular Type
C57BL/6
Balb/c
Nude mice
CB-17 SCID
NOG
NCG
NSG
Transgenic mice
SD/CD mice
Immune checkpoint
Tumor markers
Autoimmunity
Tumor microenvironment
Angiogenesis
Immunoregulation
Cytokine
ADC
Monoclonal antibody
Polyspecific antibody
Recombinant protein
mRNA
Small molecules
Batch-to batch consistency in cell resources with high stability and low within-group variation. The tumor growth curves of the existing models are as follows:
2. Standardized laboratory animal facility
Sanyou has rented SPF /Elite animal facility, high-quality laboratory mice and meet animal ethics requirements.
3. Extensive experience in project research and development
3.1. Extensive experience in target animal models
As shown in Table 2, Sanyou Bio has successfully established a series of target candidate molecules, covering dozens of popular targets regarding immunity, autoimmune disorders and metabolism, and we are accumulated in rich project experience for different anti-tumor agents, covering Antibodies, Bi/Tri-specific Antibody, Antibody–drug conjugates and recombinant proteins.
Table 2 In-vivo efficiency evaluation with profile
Target
MOA
Solution 1
Solution 2
Reference 1
Reference 2
TIGIT
Immune checkpoint
hTIGIT-mice
A375-PBMC humanized mice
Tiragolumab
PVRIG
Immune checkpoint
hPVRIG-mice
PBMC humanized mice
COM701
TNFR2
Immunity
hTNFR2-mice
PBMC humanized mice
Opi Vi
CTLA-4
Immune checkpoint
hCTLA-4-mice
PBMC humanized mice
Ipilimumab
EGFR
RTKs
A431
FaDu
Centuximab
Panitumumab
4-1BB
Immunity
CT26
MC38
ABL111
ADG106
CD39
Immunity
MOLP-8
TTX030
ROR1
ADC
A549
MDA-MB-231
Cirmtuzumab
Trop2
ADC
A431
MDA-MB-231
Sacituzumab
CLDN6
Cancer-associated markers
PA-1
CLDN6-OV90
IMAB027
LAG3
Immunity
hLAG3-mice
PBMC humanized mice
Relatlimab
HLX26
CD47
Immunity
Raji
SKOV-3
Magrolimab
lemzoparlimab
PD-L1
Immune checkpoint
hPD-L1-mice
PBMC humanized mice
Atezolizumab
Durvalumab
PD-1
Immune checkpoint
hPD-1-mice
PBMC humanized mice
Pembrolizumab
Nivolumab
VEGF
Angiogenesis
COLO-205
A431
Bevacizumab
Ramucirumab
ANGPTL3
Cardiovascular
DIOObesity model
Evinacumab
ALX
RTKs
A549
MDA-MB-231
Enapotamab
DDR1
Immunity
CT26
B16-F10
U.Texas
CLDN18.2
Cancer-associated markers
MC38-hCLDN18.2
HEK293-hCLDN18.2
IMAB362
CD40
Immunity
hCD40-mice
Selicrelumab
HER2
RTKs
BT474
N87
Trastuzumab
Pertuzumab
CD24
Cancer-associated markers
HT29
MCF-7
Tel Aviv U
CD100
Immunity
CT-26
PBMC humanized mice
Pamrevlumab
TSLP
Autoimmune
OVA Model
Tezepelumab
BCMA
Cancer-associated markers
NCI-H929
MM.1S
GSK2857916
Case Stastics
1. 4-1BB: Synergistic CT-26 colon model
Synergistic CT26 colon cancer model in Balb/c mice is shown in Fig. 1. The mice were divided into control group and treatment group, and then they were intraperitoneally administered BIW.3 (twice per week for three weeks). Antibody A dosed at 3 MPK showed 95% tumor inhibition, which could significantly inhibit tumor growth.
Fig. 1 Tumor growth inhibition
2. HER2: Xenograft N87 gastric cancer model
Xenograft N87 gastric cancer model in nude mice is shown in Fig. 2. The mice were divided into control group and treatment group, and then they were intraperitoneally administered BIW.4 (twice per week for four weeks). The results showed that Antibody B dosed at 20 MPK display 85.5% tumor inhibition and Antibody C dosed at 20 MPK has 53% tumor inhibition.
Fig. 2 Tumor growth inhibition
3. VEGF: Xenograft COLO-205 colon cancer model
Xenograft COLO-205 colon cancer model in nude mice is shown in Fig. 3. The mice were divided into control group and treatment group, and then they were intraperitoneally administered BIW.3 (twice per week for three weeks). The results showed that tumor inhibition of Bevacizumab dosed at 0.95 MPK is as high as 42%.
Fig. 3 Tumor growth inhibition
4. CD47: Xenograft Raji lymphoma model
Xenograft Raji lymphoma model in NOD/ SCID mice model is shown in Fig. 4. The mice were divided into control group and treatment group, and then they were intravenously administered BIW.3 (twice per week for three weeks). The results showed that magrolimab has dosage-dependent tumor growth inhibition. Tumor inhibition of Magrolimab dosed at 5 MPK is as high as 89.3%, which could significantly inhibit tumor growth, indicating that the model was successfully constructed.
Fig. 4 Tumor growth inhibition
5. BCMA: Xenograft MM 1S myeloma model
Xenograft MM.1S myeloma model in NOD/ SCID mice is shown in Fig. 5. The mice were divided into control group and treatment group, and then they were intravenously administered BIW.3 (twice per week for three weeks). The results showed tumor inhibition of GSK2857916 dosed at 5 MPK is up to 53%, indicating that the model was successfully constructed.
Fig. 5 Tumor growth inhibition
6. CD40: Xenograft Romas lymphoma model
Xenograft Romas lymphoma model in Balb/c nude mice is shown in Fig. 6. The mice were divided into control group and treatment group, and then they were intraperitoneally administered BIW.3 (twice per week for three weeks). The results showed that the tumor inhibition of APX005 dosed at 5 MPK is 92.7%.
Fig. 6 Tumor growth inhibition
7. MOLP-8 Xenograft myeloma model
Xenograft MOLP-8 myeloma model in NCG mice is shown in Fig. 7. The mice were divided into control group and treatment group, and then they were intraperitoneally administered BIW.3 (twice per week for three weeks). The results showed that competitor D could inhibit tumor growth, indicating that the model was successfully constructed.
Fig. 7 Tumor growth inhibition
8. CTLA-4: Synergistic MC38 colon cancer model
Synergistic MC38 colon cancer in CTLA-4 humanized mice is shown in Fig. 8. The mice were divided into control group and treatment group, and then they were intraperitoneally administered TIW.3 (three times per week for three weeks). The results showed that ipilimumab has a dose-dependent tumor inhibitory effect, and ipilimumab dosed at 2 MPK has tumor inhibition rate of 99%, indicating that the model was successfully constructed.
Fig. 8 Tumor growth inhibition
9. TNFR2: Synergistic MC38 colon cancer model
Synergistic MC38 colon cancer in in TNFR2 humanized mice is shown in Fig. 9. The mice were divided into control group and treatment group, and then they were intraperitoneally administered BIW.3 (twice per week for three weeks). The results showed that the tumor inhibition rate of OPI is 99.9% at the dose of 15 MPK, indicating that the model was successfully constructed.
Fig. 9 Tumor growth inhibition
10. LAG3: Synergistic MC38 colon cancer model
Synergistic MC38 colon cancer in LAG3 humanized mice is shown in FIG. 10. The mice were divided into control group and treatment group, and then they were intraperitoneally administered BIW.3 (twice per week for three weeks). The results showed that the tumor inhibition rate of avelumab and relatimab combination is 76.2%, which could significantly inhibit tumor growth, indicating that the model was successfully constructed.
Fig. 10 Tumor growth inhibition
11. EGFR: Xenograft A431 head and neck cancer model
Xenograft A431 head and neck cancer model in NCG mice is shown in FIG. 11. The mice were divided into control group and treatment group, and then they were intraperitoneally administered BIW.3 (twice a week for consecutive three weeks). The results showed that the tumor inhibition rate of Panitumumab is 84.8% at the dose of 0.7 MPK, which could significantly inhibit tumor growth, indicating that the model was successfully constructed.
Fig. 11 Tumor growth inhibition
12. ADC: Xenograft HT-29 colon cancer model
Xenograft HT-29 colon cancer model in Balb/c nude mice is shown in Fig. 12. The mice were divided into control group and treatment group, and then they were intravenously administered BIW.4 (twice a week for consecutive four weeks). The results showed that the tumor inhibition rate of competitor E-MMAE was 89.3%, which could significantly inhibit tumor growth, indicating that the model was successfully constructed.
Fig. 12 Tumor growth inhibition
13. TriAb: Xenograft N87 gastric cancer model
Xenograft N87 gastric cancer model in NCG humanized PBMC mice is shown in Fig. 13. The mice were divided into control group and treatment group, and then they were intravenously administered twice a week for four weeks. The results showed that TriAb has synergistic effect, and the tumor inhibition rate of TriAb was up to 83.4% at the same molar dose, indicating that the model could be used to evaluate the efficacy of tri-specific antibodies.
Fig. 13 Tumor growth inhibition
14. PD-L1/ VEGF combination: Xenograft COLO205 colon cancer model
Xenograft COLO-205 colon cancer model in NCG humanized PBMC mice is shown in Fig. 14. The mice were divided into control group and treatment group, and then they were intravenously administered twice a week for two weeks. The results showed synergistic effect, and BsAb has the tumor inhibition rate as high as 90.6% at the same molar dose, which showed that the model could be used to evaluate the efficacy of bispecific antibody.
Fig. 14 Tumor growth inhibition
15. Biomarkers detection
After the in vivo efficacy evaluation of antibody, the liver of mice was taken and tested for alanine aminotransferase (ALT) and aspartate aminotransferase (AST) to evaluate its hepatotoxicity. The results were shown in FIG. 15, the ALT and AST levels of BM was consistent with the patent, indicating that the detection method was reliable.
Fig. 15 The levels of ALT and AST in mice liver